CoChat

PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages – a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation

Open access

The DOI matches its Crossref record; 61 of the 63 references it cites were found in a registry or an index.

Abstract

Background and objectives: Progesterone is essential to maintain a healthy pregnancy. Guidance from the Royal College of Obstetricians and Gynaecologists and a Cochrane review called for a definitive trial to test whether or not progesterone therapy in the first trimester could reduce the risk of miscarriage in women with a history of unexplained recurrent miscarriage (RM). The PROMISE trial was conducted to answer this question. A concurrent cost-effectiveness analysis was conducted. Design and setting: A randomised, double-blind, placebo-controlled, international multicentre study, with economic evaluation, conducted in hospital settings across the UK (36 sites) and in the Netherlands (nine sites). Participants and interventions: Women with unexplained RM (three or more first-trimester losses), aged between 18 and 39 years at randomisation, conceiving naturally and giving informed consent, received either micronised progesterone (Utrogestan®, Besins Healthcare) at a dose of 400 mg (two vaginal capsules of 200 mg) or placebo vaginal capsules twice daily, administered vaginally from soon after a positive urinary pregnancy test (and no later than 6 weeks of gestation) until 12 completed weeks of gestation (or earlier if the pregnancy ended before 12 weeks). Main outcome measures: Live birth beyond 24 completed weeks of gestation (primary outcome), clinical pregnancy at 6–8 weeks, ongoing pregnancy at 12 weeks, miscarriage, gestation at delivery, neonatal survival at 28 days of life, congenital abnormalities and resource use. Methods: Participants were randomised after confirmation of pregnancy. Randomisation was performed online via a secure internet facility. Data were collected on four occasions of outcome assessment after randomisation, up to 28 days after birth. Results: A total of 1568 participants were screened for eligibility. Of the 836 women randomised between 2010 and 2013, 404 received progesterone and 432 received placebo. The baseline data (age, body mass index, maternal ethnicity, smoking status and parity) of the participants were comparable in the two arms of the trial. The follow-up rate to primary outcome was 826 out of 836 (98.8%). The live birth rate in the progesterone group was 65.8% (262/398) and in the placebo group it was 63.3% (271/428), giving a relative risk of 1.04 (95% confidence interval 0.94 to 1.15;p = 0.45). There was no evidence of a significant difference between the groups for any of the secondary outcomes. Economic analysis suggested a favourable incremental cost-effectiveness ratio for decision-making but wide confidence intervals indicated a high level of uncertainty in the health benefits. Additional sensitivity analysis suggested the probability that progesterone would fall within the National Institute for Health and Care Excellence’s threshold of £20,000–30,000 per quality-adjusted life-year as between 0.7145 and 0.7341. Conclusions: There is no evidence that first-trimester progesterone therapy improves outcomes in women with a history of unexplained RM. Limitations: This study did not explore the effect of treatment with other progesterone preparations or treatment during the luteal phase of the menstrual cycle. Future work: Future research could explore the efficacy of progesterone supplementation administered during the luteal phase of the menstrual cycle in women attempting natural conception despite a history of RM. Trial registration: Current Controlled Trials ISRCTN92644181; EudraCT 2009-011208-42; Research Ethics Committee 09/H1208/44. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 41. See the NIHR Journals Library website for further project information.

Overview

Integrity signals

Registry

Crossref · 10.3310/hta20410

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 61 references

Research works printed but not linked: 25

  1. Regan, 2003, The Investigation and Treatment of Couples with Recurrent Miscarriage
  2. d-maps.com, United Kingdom/United Kingdom of Great Britain and Northern Ireland: Outlines, Nations, Color (White)
  3. d-maps.com, Netherlands/Koninkrijk der Nederlanden: Outline, Provinces, Color (White)
  4. US Food and Drug Administration Advisory Committee for Reproductive Health Drugs, 2003, Briefing Information for the September 29, 2003 Meeting of the Advisory Committee for Reproductive Health Drugs
  5. European Commission, 2003, Commission Directive 2003/94/EC of 8 October 2003
  6. European Commission, 2001, Commission Directive 2001/20/EC of 4 April 2001
  7. EudraLex, 2010, The Rules Governing Medicinal Products in the European Union, Volume 4: Guidelines for Good Manufacturing Practices for Medicinal Products for Human and Veterinary Use – Annex 13, Manufacture of Investigational Medicinal Products
  8. Datapharm, Utrogestan Vaginal 200 mg Capsules – Summary of Product Characteristics
  9. Joint Formulary Committee, 2014, British National Formulary
  10. Great Britain, 2006, The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006
  11. Royal Pharmaceutical Society of Great Britain, 2005, The Safe and Secure Handling of Medicines: A Team Approach
  12. National Pharmacy Clinical Trials Advisory Group, 2013, Professional Guidance on Pharmacy Services for Clinical Trials, Version 1
  13. Imperial College London/Imperial College Healthcare NHS Trust Joint Research Compliance Office, 2015, Recording Managing and Reporting Adverse Events in the UK Imperial College of Science Technology and Medicine, Version 7.0
  14. Medical Research Council/Department of Health, Clinical Trials Toolkit 2007. Work Stream 6: Pharmacovigilance (Updated 2012)
  15. European Commission, 2006, Detailed Guidance on the Collection, Verification and Presentation of Adverse Reaction Reports arising from Clinical Trials on Medicinal Products for Human Use: Revision 2
  16. Great Britain, 1998, Data Protection Act 1998
  17. Department of Health, 2003, Confidentiality: NHS Code of Practice
  18. Department of Health, The Caldicott Committee, 1997, Report on the Review of Patient-Identifiable Information
  19. Department of Health, 2005, Research Governance Framework for Health and Social Care, Second Edition
  20. Involve, 2009, Public Involvement in the Management for the Research Design Service
  21. Gardosi, 2013, Customised Weight Centile Calculator
  22. Department of Health, 2012, Reference Costs 2011–12
  23. National Collaborating Centre for Women’s and Children’s Health, 2012, Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management in Early Pregnancy of Ectopic Pregnancy and Miscarriage
  24. Maternal Critical Care Working Group, 2011, Providing Equity of Critical and Maternity Care for the Critically Ill Pregnant or Recently Pregnant Woman
  25. National Institute for Health and Care Excellence, 2013, Guide to the Methods of Technology Appraisal 2013

Cited by

Items 101–109 of 109

Metadata

Authors
Coomarasamy, A., Williams, H., Truchanowicz, E., Seed, P. T., Small, R., Quenby, S., Gupta, P., Dawood, F., Koot, Y. E., Atik, R. B., Bloemenkamp, K. W., Brady, R., Briley, A., Cavallaro, R., Cheong, Y. C., Chu, J., Eapen, A., Essex, H., Ewies, A., Hoek, A., Kaaijk, E. M., Koks, C. A., Li, T.-C., MacLean, M., Mol, B. W., Moore, J., Parrott, S., Ross, J. A., Sharpe, L., Stewart, J., Trépel, D., Vaithilingam, N., Farquharson, R. G., Kilby, M. D., Khalaf, Y., Goddijn, M., Regan, L., & Rai, R.
Affiliations
  • University of Birmingham (GB)
  • St Thomas' Hospital (GB)
  • Heart of England NHS Foundation Trust (GB)
  • University of Warwick (GB)
  • Liverpool Women's Hospital (GB)
  • University Medical Center Utrecht (NL)
  • The Miscarriage Association, Wakefield, UK
  • Leiden University Medical Center (NL)
  • St Mary's Hospital (GB)
  • Princess Anne Hospital (GB)
  • University of York (GB)
  • Sandwell & West Birmingham Hospitals NHS Trust (GB)
  • University Medical Center Groningen (NL)
  • OLVG (NL)
  • Máxima Medisch Centrum (NL)
  • Royal Hallamshire Hospital (GB)
  • University Hospital Crosshouse (GB)
  • The University of Adelaide (AU)
  • Nottingham University Hospitals NHS Trust (GB)
  • King's College Hospital NHS Foundation Trust (GB)
  • Royal Victoria Infirmary (GB)
  • Queen Alexandra Hospital (GB)
  • Guy's Hospital (GB)
  • Amsterdam UMC Location University of Amsterdam (NL)
Corresponding author
Coomarasamy, Arri
Venue
Health Technology Assessment
Published
2016-05
Volume
20
Issue
41
Pages
1-92
ISSN
  • 1366-5278 (ISSN-L)
  • 2046-4924
OpenAlex
W2403936163
Cited by
109
References
63
Citations by year
2026: 6 · 2025: 8 · 2024: 12 · 2023: 15 · 2022: 9 · 2021: 15 · 2020: 8 · 2019: 13 · 2018: 7 · 2017: 13 · 2016: 1
FWCI
6.87
Type
journal article
Language
en
Open access
Locations
  • Health Technology Assessment (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • ePrints Soton (University of Southampton) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion, cc-by-nc)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
  • Spiral (Imperial College London) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Funders
Health Technology Assessment programme (08/38/01)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
Keywords
progesterone therapy, unexplained recurrent spontaneous abortion, early pregnancy loss, Utrogestan, live birth rate, clinical pregnancy, ongoing pregnancy, cost-effectiveness, economic evaluation, congenital malformations, neonatal survival, resource utilization (health care), pregnancy loss prevention, spontaneous conception, PROMISE trial
MeSH terms
Congenital Abnormalities, Abortion, Habitual, Administration, Intravaginal, Adolescent, Adult, Cost-Benefit Analysis, Double-Blind Method, Female, Gestational Age, United Kingdom, Humans, Infant, Infant Mortality, Netherlands, Pregnancy, Pregnancy Outcome, Pregnancy Trimester, First, Progesterone, Quality-Adjusted Life Years, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.